Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Thromb Haemost ; 20(4): 996-1007, 2022 04.
Article in English | MEDLINE | ID: mdl-35037739

ABSTRACT

BACKGROUND: Atrial fibrillation (AF) can lead to the loss of microvascular integrity thereby enhancing AF progression. Mechanistically, the pro-coagulant state that drives the risk of stroke in patients with AF may also play a causal role in microvascular loss. Direct oral anticoagulants (DOACs), the preferred anticoagulants for AF, can target factors upstream (factor Xa [FXa]) or downstream (thrombin) in the coagulation cascade and mediate differential vascular effects through interaction with protease-activated receptors (PARs). OBJECTIVE: To investigate the potential effect of different DOACs on vascular integrity. METHODS: To model the impact of DOACs on vascular integrity, we utilized platelet-free plasma in thrombin generation assays and endothelial barrier assays under identical experimental conditions. These multifactorial systems provide all coagulation factors and their respective natural inhibitors in physiological ratios in combination with the pro-coagulant endothelial surface on which coagulation is initiated. Furthermore, the system provides pro- and anti-barrier factors and monitoring both assays simultaneously permits coupling of thrombin kinetics to endothelial barrier dynamics. RESULTS: We provide evidence that the anti-FXa DOAC rivaroxaban and the anti-thrombin DOAC dabigatran are efficient in blocking their target proteases. However, while rivaroxaban could preserve endothelial barrier function, dabigatran failed to protect endothelial integrity over time, which could be prevented in the presence of a custom-made peptide that blocks thrombin's exosite-I. CONCLUSIONS: Proteolytically inactive thrombin in complex with dabigatran evokes loss of barrier function that can be prevented by a protease-activated receptor-1 mimicking peptide blocking thrombin's exosite-I.


Subject(s)
Atrial Fibrillation , Dabigatran , Administration, Oral , Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Dabigatran/adverse effects , Factor Xa/therapeutic use , Factor Xa Inhibitors/adverse effects , Humans , Receptor, PAR-1 , Rivaroxaban/adverse effects , Thrombin/therapeutic use
2.
Thromb Haemost ; 120(4): 538-564, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32289858

ABSTRACT

Thrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating cells and thrombo-inflammation, focused on platelets, neutrophils, and neutrophil extracellular traps; (3) procoagulant mechanisms; (4) arterial vascular changes in atherogenesis; attenuating atherosclerosis and ischemia/reperfusion injury; (5) management of patients with arterial vascular disease; and (6) pathogenesis of venous thrombosis and late consequences of venous thromboembolism.


Subject(s)
Atherosclerosis/immunology , Cardiovascular Diseases/immunology , Endothelium, Vascular/physiology , Inflammation/immunology , Neutrophils/immunology , Venous Thromboembolism/immunology , Animals , Atherosclerosis/diagnosis , Atherosclerosis/therapy , Blood Coagulation , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/therapy , Expert Testimony , Humans , Immunity, Innate , Thrombosis , Venous Thromboembolism/diagnosis , Venous Thromboembolism/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...